TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17416906

Group type: EXPERIMENTAL
Intervention: GR79236X 4 microg kg‐1
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GR79236X 10 microg kg‐1
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 16281834

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacine (0.5 g) 90‐120 min before TUR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacine (0.4 g) 30‐60 min before TUR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis (control)
Number of subjects: 120
Study: 12217104

Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Videoconferencing
Number of subjects: 24
Study: 10461844

Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime administered intravenously 10 min before surgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no cefuroxime)
Number of subjects: 59
Study: 8594657

Group type: EXPERIMENTAL
Intervention: Lobenzarit disodium (CCA) in combination with sodium aurothiomalate and D-penicillamine (group-A)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sodium aurothiomalate or D-penicillamine (group-B)
Number of subjects: 157
Study: 1971165

Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg)
Number of subjects: 12
Study: 7369913

Group type: EXPERIMENTAL
Intervention: 500 mg cefaclor
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1 g cefaclor
Number of subjects: 39
Study: 29952733

Group type: EXPERIMENTAL
Intervention: New ergonomic seat prototype
Number of subjects: 20

Group type: COMPARATOR
Intervention: Industrial standard seat
Number of subjects: 20
Study: 27399595

Group type: EXPERIMENTAL
Intervention: DBT-PTSD
Number of subjects: 0
Study: 25795376

Group type: EXPERIMENTAL
Intervention: Rhinoplasty including cutting and repositioning of the depressor septi nasi muscle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rhinoplasty without manipulation of the depressor septi nasi muscle (control)
Number of subjects: 80
Study: 23252444

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: High-frequency physical therapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study: 21497001

Group type: EXPERIMENTAL
Intervention: Partial wound closure (group I)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Total wound closure (group II)
Number of subjects: 82
Study: 19539473

Group type: EXPERIMENTAL
Intervention: Classification system for delirium subtypes using a commercial accelerometer-based activity monitor
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Classification trees based on periods of sitting/lying, standing, stepping, and number of postural transitions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Observed ward behavior
Number of subjects: 40
Study: 17476469

Group type: EXPERIMENTAL
Intervention: Extended hemodynamic monitoring with anesthesiologists aware of CI results
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine hemodynamic monitoring with anesthesiologists blinded to CI results
Number of subjects: 28
Study: 14701778

Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) 5 mg/kg/d with whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions
Number of subjects: 401

Group type: COMPARATOR
Intervention: Whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions without motexafin gadolinium (MGd)
Number of subjects: 401
Study: 11530563

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9180238

Group type: EXPERIMENTAL
Intervention: Lipid-modulating therapy that lowers LDL cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid-modulating therapy that lowers LDL cholesterol and decreases serum triglyceride and/or increases HDL cholesterol
Number of subjects: 0
Study: 8506881

Group type: EXPERIMENTAL
Intervention: Small-group education
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Individual education
Number of subjects: 323

Group type: COMPARATOR
Intervention: Usual control (no formal asthma education)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Information (workbook) control
Number of subjects: 323
Study: 3325929

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole plus colistin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 56
Study: 30354767

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27999883

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg in pediatric subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg in pediatric subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alogliptin 25 mg in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 0
Study: 26465928

Group type: EXPERIMENTAL
Intervention: Supplemental decision support alert for critically low systolic blood pressure (SBP)
Number of subjects: 3165

Group type: COMPARATOR
Intervention: Routine management (no alerts)
Number of subjects: 3165
Study: 23260415

Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22030233

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 40mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 20mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide, 40mg and 20mg
Number of subjects: 79
Study: 18463518

Group type: EXPERIMENTAL
Intervention: 2 mg IVTA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 4 mg IVTA
Number of subjects: 28
Study: 16571278

Group type: EXPERIMENTAL
Intervention: Jiawei Huangqi Guizhi Wuwu Decoction (JHGWD) combined with chemotherapy and oxaliplatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 31
Study: 12928469

Group type: EXPERIMENTAL
Intervention: Trials funded by nonprofit organizations
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Trials not reporting funding
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Trials funded by both nonprofit and for-profit organizations
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Trials funded by for-profit organizations
Number of subjects: 370
Study: 11144398

Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg daily (QD)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg twice a day (BID)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 40/10 mg/kg/day divided TID
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg BID
Number of subjects: 384

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 384
Study: 9225366

Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin‐3 (rhIL‐3) at doses of 0.5, 1.0, 5.0, 7.5, and 10 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant human Interleukin‐3 (rhIL‐3) at 10 micrograms/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cycles (no cytokine therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant human Granulocyte‐Macrophage Colony‐Stimulating Factor (rhGM‐CSF) at 3.0 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cytokine treatment (rhIL‐3 and rhGM‐CSF)
Number of subjects: 30
Study: 8452175

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg once a day)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Ceftazidime (0.5‐2 g three times a day or 1‐2 g twice a day)
Number of subjects: 316
Study: 3732047

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy in initial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 31144852

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Therapist behaviors in early sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PQS prototypes
Number of subjects: 20
Study: 28056021

Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 4 weeks (DOX 4w)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 3 weeks plus ALB 800mg/d for 3 days (DOX 3w + ALB 3d)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MIN 200mg/d for 3 weeks (MIN 3w)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DOX 200mg/d for 3 weeks (DOX 3w)
Number of subjects: 158

Group type: COMPARATOR
Intervention: ALB 800mg for 3 days (ALB 3d)
Number of subjects: 158
Study: 25885678

Group type: EXPERIMENTAL
Intervention: Maternal verbal report
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unused returned medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma nevirapine concentration >100 ng/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal verbal reports
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Missed doses by maternal verbal reports
Number of subjects: 0
Study: 23449923

Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 707

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 707
Study: 20809267

Group type: EXPERIMENTAL
Intervention: Selenium-enriched chicken (4 portions of 200 g/week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-enriched chicken (4 portions of 200 g/week)
Number of subjects: 24
Study: 17717532

Group type: EXPERIMENTAL
Intervention: Sulfurous mineral water (500 ml day(‐1) for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without sulfurous mineral water)
Number of subjects: 40
Study: 17353434

Group type: EXPERIMENTAL
Intervention: Noninvasive evaluation using 64‐slice multislice computed tomography
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with severe mitral regurgitation
Number of subjects: 105
Study: 15569141

Group type: EXPERIMENTAL
Intervention: Enhanced care using Asian link workers and extra community diabetes specialist nurse sessions
Number of subjects: 361

Group type: COMPARATOR
Intervention: Standard practice care
Number of subjects: 361
Study: 11419888

Group type: EXPERIMENTAL
Intervention: Abciximab bolus plus 12-h infusion
Number of subjects: 9290

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 9290
Study: 9405748

Group type: EXPERIMENTAL
Intervention: Endoscopic intervention for removal of gallstones and reestablishment of biliary drainage
Number of subjects: 800
Study: 8728734

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with 30% PIMax
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with 10% PIMax
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crossover after 10 weeks
Number of subjects: 20
Study: 2600754

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 973673

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Extended field radiotherapy
Number of subjects: 44
Study: 31915189

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overnight sleep loss
Number of subjects: 15
Study: 30196572

Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent (SES)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (SES)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (BRS)
Number of subjects: 148
Study: 28515160

Group type: EXPERIMENTAL
Intervention: Epro and UFA condition
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carbohydrate condition
Number of subjects: 25
Study: 26200146

Group type: EXPERIMENTAL
Intervention: 2% CHX solution for 60 s after acid etching and before adhesive application
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 42
Study: 23637033

Group type: EXPERIMENTAL
Intervention: Catheter-over-needle group (received a second bolus of 20 mL of 0.2% ropivacaine postoperatively)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-shot group (received 25-30 mL of 1.5% lidocaine and 0.125% bupivacaine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Catheter-over-needle group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-shot group
Number of subjects: 30
Study: 21269402

Group type: EXPERIMENTAL
Intervention: Testosterone pellets (75 mg each, 8 to 12 pellets, total 450 mg to 900 mg)
Number of subjects: 0
Study: 18563471

Group type: EXPERIMENTAL
Intervention: Reboxetine (4-6 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Methylphenidate (20-50 mg/d)
Number of subjects: 33
Study: 17586417

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/HCTZ 12.5 mg
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ 12.5 mg
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/HCTZ (stage 2 hypertension)
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ (stage 2 hypertension)
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/HCTZ (stage 1 hypertension)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4278
Study: 15556954

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Combined treatment (manipulation followed by exercise)
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Best care
Number of subjects: 1287
Study: 11162286

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9158189

Group type: EXPERIMENTAL
Intervention: Technetium-99m-sestamibi scintigraphy (MIBI scintigraphy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physical and histological examination
Number of subjects: 36
Study: 7900078

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg body weight (mean 75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin (high dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excess platelet factor 4 (PF4)
Number of subjects: 0
Study: 2839439

Group type: EXPERIMENTAL
Intervention: Concurrent Platinum (DDP) Etoposide (VP‐16) chemotherapy and twice‐daily, 150 cGy radiotherapy to a total dose of 4500 cGy in 3 weeks.
Number of subjects: 23
Study: 31701163

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 67
Study: 25116293

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham Acupuncture (SHAM)
Number of subjects: 24
Study: 23168166

Group type: EXPERIMENTAL
Intervention: Standardized stretch force method for assessing flexibility
Number of subjects: 10
Study: 21974760

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ 160/12.5 mg, titrated to 320/25 mg at week 4
Number of subjects: 401

Group type: COMPARATOR
Intervention: Amlodipine/HCTZ (HCTZ 12.5 mg monotherapy, then amlodipine 5 mg at week 8 and 10 mg at week 12)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 401

Group type: COMPARATOR
Intervention: Amlodipine/HCTZ
Number of subjects: 401
Study: 18381905

Group type: EXPERIMENTAL
Intervention: DMXB-A (higher dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DMXB-A (lower dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DMXB-A (first treatment arm)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17532523

Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resiquimod 0.02 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14764932

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS) and contrast‐enhanced MR angiography (CEMRA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS) and CT angiography (CTA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Contrast‐enhanced MR angiography (CEMRA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Doppler ultrasound (DUS)
Number of subjects: 150
Study: 11324378

Group type: EXPERIMENTAL
Intervention: Patients with dementia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ageing
Number of subjects: 0
Study: 9450162

Group type: EXPERIMENTAL
Intervention: Sodium valproate (300 mg, Orfiril long) after fasting
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium valproate (300 mg, Orfiril long) after a high energy high fat breakfast
Number of subjects: 16
Study: 8192698

Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered in a fasting state
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered after a standard meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 350 mg sustained-release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Co-administration of food with theophylline
Number of subjects: 18
Study: 3310776

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1

Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 1
Study: 30306604

Group type: EXPERIMENTAL
Intervention: 200 μg l-selenomethionine daily for 6 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 28114798

Group type: EXPERIMENTAL
Intervention: Intermittent metoclopramide infusion (10 mg every 6 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous metoclopramide infusion (2 mg/h)
Number of subjects: 40
Study: 26541435

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed
Number of subjects: 1084
Study: 24687826

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day for 10 weeks
Number of subjects: 169

Group type: COMPARATOR
Intervention: Sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Physician preference
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HRQoL measures
Number of subjects: 169
Study: 23294071

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 60
Study: 19297565

Group type: EXPERIMENTAL
Intervention: Annual screening with PSA testing and digital rectal examination
Number of subjects: 76693

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 76693
Study: 17968163

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation (40 Gy plus 5-FU)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Observation (no further adjuvant treatment)
Number of subjects: 218
Study: 15573278

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Coronary interventions
Number of subjects: 361
Study: 11770837

Group type: EXPERIMENTAL
Intervention: Ciprofibrate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 9670578

Group type: EXPERIMENTAL
Intervention: Triple therapy (Amoxycillin, Clarithromycin, Omeprazole) for 6 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Monotherapy (Omeprazole) for 6 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Monotherapy (Omeprazole)
Number of subjects: 88
Study: 10147193

Group type: EXPERIMENTAL
Intervention: Worksite alcohol program
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo (nutrition) program
Number of subjects: 268

Group type: COMPARATOR
Intervention: No program
Number of subjects: 268
Study: 2452456

Group type: EXPERIMENTAL
Intervention: 3 g GVG per day for 3 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1.5 g GVG per day for 3 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GVG treatment
Number of subjects: 78
Study: 31913927

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 127
Study: 31373737

Group type: EXPERIMENTAL
Intervention: Earthworms + duckweed (group M)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Duckweed (group P)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Earthworms (group A)
Number of subjects: 270
Study: 28125907

Group type: EXPERIMENTAL
Intervention: Nutreal (ready-to-use therapeutic food)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Defined food (homemade diet)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nutreal
Number of subjects: 112

Group type: COMPARATOR
Intervention: Defined food
Number of subjects: 112
Study: 25843270

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Licensed inactivated trivalent influenza vaccine (IIV3)
Number of subjects: 1977